Back to Search Start Over

Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia

Authors :
Francesco Giallauria
Angela Marsili
Alessandro Filla
Andrea Salzano
Assunta Trinchillo
Giovanni Defazio
Claudia Del Prete
Francesco Saccà
Vincenzo Guardasole
Giovanna De Michele
Giorgia Puorro
Rossella Vastarella
Carlo Casali
Christian Marcotulli
Chiara Pane
Antonio Cittadini
Pane, Chiara
Salzano, Andrea
Trinchillo, Assunta
Del Prete, Claudia
Casali, Carlo
Marcotulli, Christian
Defazio, Giovanni
Guardasole, Vincenzo
Vastarella, Rossella
Giallauria, Francesco
Puorro, Giorgia
Marsili, Angela
De Michele, Giovanna
Filla, Alessandro
Cittadini, Antonio
Saccà, Francesco
Source :
European Journal of Preventive Cardiology. 29:445-451
Publication Year :
2020
Publisher :
Oxford University Press (OUP), 2020.

Abstract

Aims To explore the feasibility of upper limbs cardiopulmonary exercise test (CPET) in Friedreich ataxia (FRDA) patients and to compare the results with sex, age, and body mass index (BMI) matched cohort of healthy controls (HC). Methods and results Cardiopulmonary exercise test was performed using an upper limbs cycle ergometer on fasting subjects. Peak oxygen uptake (peak VO2) was recorded as the mean value of VO2 during a 20 s period at the maximal effort of the test at an appropriate respiratory exchange rate. The ventilatory anaerobic threshold (AT) was detected by the use of the V-slope method. We performed echocardiography with an ultrasound system equipped with a 2.5 MHz multifrequency transducer for complete M-mode, two-dimensional, Doppler, and Tissue Doppler Imaging analyses. We studied 55 FRDA and 54 healthy matched controls (HC). Peak VO2 showed a significant 31% reduction in FRDA patients compared to HC (15.2 ± 5.7 vs. 22.0 ± 6.1 mL/kg/min; P Conclusions Upper limb CPET is useful in the assessment of exercise tolerance and a possible tool to determine the functional severity of the mitochondrial oxidative defect in patients with FRDA. The cardiopulmonary exercise test is an ideal functional endpoint for Phases II and III trials through a simple, non-invasive, and safe exercise test.

Details

ISSN :
20474881 and 20474873
Volume :
29
Database :
OpenAIRE
Journal :
European Journal of Preventive Cardiology
Accession number :
edsair.doi.dedup.....56e9b724ebe38b4e9ac3c03b69936f08
Full Text :
https://doi.org/10.1093/eurjpc/zwaa134